Key Developments: Kaiser Aluminum Corp (KALU.OQ)

KALU.OQ on NASDAQ Stock Exchange Global Select Market

70.84USD
4:00pm EDT
Price Change (% chg)

$-1.71 (-2.36%)
Prev Close
$72.55
Open
$71.61
Day's High
$72.27
Day's Low
$70.55
Volume
105,382
Avg. Vol
77,889
52-wk High
$74.08
52-wk Low
$59.36

Search Stocks

Latest Key Developments (Source: Significant Developments)

Kaiser Aluminum Corporation Announces Upsizing And Pricing Of Senior Notes Offering
Friday, 18 May 2012 04:30pm EDT 

Kaiser Aluminum Corporation announced that it has priced its previously announced offering of $225.0 million in aggregate principal amount of 8.25% senior notes due 2020 (the notes) in a private transaction that is exempt from the registration requirements of the Securities Act of 1933 (the Act). This represents an increase of $25.0 million over the amount previously announced. The notes will be guaranteed by each of Kaiser Aluminum's existing and future domestic subsidiaries that is a borrower or guarantor under Kaiser Aluminum's revolving credit facility. Kaiser Aluminum intends to use the net proceeds from the offering of the notes for general corporate purposes, which may include, among other things, acquisitions. The consummation of the offering of notes is expected to be completed on May 23, 2012, subject to customary closing conditions.  Full Article

Kaiser Aluminum Corporation Announces Private Placement Of Senior Notes
Monday, 14 May 2012 06:40am EDT 

Kaiser Aluminum Corporation announced that it plans to offer $200.0 million aggregate principal amount of senior notes due 2020 (the notes) in a private transaction that is exempt from the registration requirements of the Securities Act of 1933 (the Act). The notes will be guaranteed by each of Kaiser Aluminum's existing and future domestic subsidiaries that is a borrower or a guarantor under Kaiser Aluminum's revolving credit facility. Kaiser Aluminum intends to use the net proceeds from the offering of the notes for general corporate purposes, which may include, among other things, acquisitions.  Full Article

Exclusive: Costs to public of $84,000 hep C drug ‘outrageous' - Kaiser

LOS ANGELES - Kaiser Permanente, the biggest U.S. health maintenance organization, said it is using Gilead Sciences' new hepatitis C drug, Sovaldi, even though its $84,000 treatment price is "outrageous."

Search Stocks